Osimertinib Plus Gefitinib in Patients with EGFR -Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD

作者：Sarah B. Goldberg, Myung‐Ju Ahn, Christina S. Baik, Javier de Castro, Byoung Chul Cho, Adrianus J. de Langen, Mary J. Fidler, Jonathan W. Goldman, Bjørn Henning Grønberg, Hiroaki Akamatsu, Sang‐We Kim, Yu Jung Kim, Xiuning Le, Kristen A. Marrone, Zofia Piotrowska, Jonathan W. Riess, Yoshimasa Shiraishi, Paula G. Fraenkel, Brayan Merchán, Paul. E. Smith, Kwan Ho Tang, Helena A. Yu · 发表于：Clinical Cancer Research · 年份：2026 · DOI：10.1158/1078-0432.ccr-26-0704 · 被引用次数：1 · 研究领域：Lung Cancer Treatments and Mutations、Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis、Lung Cancer Diagnosis and Treatment

PURPOSE: ORCHARD (NCT03944772) was a phase II, open-label study evaluating resistance mechanisms and post-progression therapies in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC) with progressive disease (PD) on first-line osimertinib. We report final data from the osimertinib plus gefitinib module in patients with EGFR C797X, a known resistance mechanism to osimertinib. METHODS: Patients received once daily osimertinib 80 mg plus gefitinib 250 mg until PD, unacceptable toxicity, or another discontinuation criterion. Primary end point was objective response rate (ORR) by investigator per RECIST 1.1. RESULTS: Thirty-one patients were treated and evaluable for response/safety (data cutoff: May 10, 2024). Eight patients had a partial response, for a confirmed ORR of 26% (80% confidence interval [CI]: 16-39); median duration of response was 4.2 months (95% CI: 2.8-5.5). Thirty patients (97%) experienced a progression-free survival (PFS) event and 19 patients (61%) died. Median PFS was 5.1 months (95% CI: 3.9-6.8) and median overall survival was 19.0 months (95% CI: 14.6-25.0). Eleven patients (35%) had grade ≥3 adverse events. Safety was consistent with the known adverse-event profiles of the individual drugs, with no new safety signals. Several resistance mechanisms (EGFR T790M, BRAF, and PIK3CA mutations) were identified following PD on osimertinib-gefitinib. CONCLUSIONS: Osimertinib-gefitinib demonstrated modest clinica...